{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:52:55Z","timestamp":1793872375740,"version":"4.6.1"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00125-020-05181-w","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T23:04:39Z","timestamp":1592521479000},"page":"1671-1693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":189,"title":["Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)"],"prefix":"10.1007","volume":"63","author":[{"given":"Wendy K.","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Erion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose C.","family":"Florez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"Hivert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark I.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan R.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Philipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison T.","family":"McElvaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Cefalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Franks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"5181_CR1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00125-017-4226-2","volume":"60","author":"AT Hattersley","year":"2017","unstructured":"Hattersley AT, Patel KA (2017) Precision diabetes: learning from monogenic diabetes. Diabetologia 60:769\u2013777","journal-title":"Diabetologia"},{"key":"5181_CR2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)60098-8","volume":"386","author":"E De Franco","year":"2015","unstructured":"De Franco E, Flanagan SE, Houghton JA et al (2015) The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet 386:957\u2013963","journal-title":"Lancet"},{"key":"5181_CR3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2337\/dc15-1111","volume":"39","author":"RA Oram","year":"2016","unstructured":"Oram RA, Patel K, Hill A et al (2016) A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care 39:337\u2013344","journal-title":"Diabetes Care"},{"key":"5181_CR4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2337\/dc18-0431","volume":"42","author":"AL Grubb","year":"2019","unstructured":"Grubb AL, McDonald TJ, Rutters F et al (2019) A type 1 diabetes genetic risk score can identify patients with GAD65 autoantibody-positive type 2 diabetes who rapidly progress to insulin therapy. Diabetes Care 42:208\u2013214","journal-title":"Diabetes Care"},{"key":"5181_CR5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2337\/dc18-1785","volume":"42","author":"SA Sharp","year":"2019","unstructured":"Sharp SA, Rich SS, Wood AR et al (2019) Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis. Diabetes Care 42:200\u2013207","journal-title":"Diabetes Care"},{"key":"5181_CR6","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/er.2019-00088","volume":"40","author":"MS Udler","year":"2019","unstructured":"Udler MS, McCarthy MI, Florez JC, Mahajan A (2019) Genetic risk scores for diabetes diagnosis and precision medicine. Endocr Rev 40:1500\u20131520","journal-title":"Endocr Rev"},{"key":"5181_CR7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S2213-8587(19)30087-7","volume":"7","author":"JM Dennis","year":"2019","unstructured":"Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2019) Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 7:442\u2013451","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5181_CR8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/dci19-0062","volume":"43","author":"GA Fleming","year":"2020","unstructured":"Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L (2020) Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care 43:250\u2013260","journal-title":"Diabetes Care"},{"key":"5181_CR9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00125-019-05034-1","volume":"63","author":"GA Fleming","year":"2020","unstructured":"Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L (2020) Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetologia 63:229\u2013241","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"5181_CR10","first-page":"S14","volume":"43","author":"ADA","year":"2020","unstructured":"ADA (2020) 2. Classification and diagnosis of diabetes. In: Standards of medical care in diabetes\u20132020. Diabetes Care 43(Suppl 1):S14\u2013S31","journal-title":"Diabetes Care"},{"key":"5181_CR11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2213-8587(17)30362-5","volume":"6","author":"NJ Thomas","year":"2018","unstructured":"Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT (2018) Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol 6:122\u2013129","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5181_CR12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00125-019-4863-8","volume":"62","author":"NJ Thomas","year":"2019","unstructured":"Thomas NJ, Lynam AL, Hill AV, Weedon MN, Shields BM, Oram RA et al (2019) Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia 62:1167\u20131172","journal-title":"Diabetologia"},{"key":"5181_CR13","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa032922","volume":"350","author":"AL Gloyn","year":"2004","unstructured":"Gloyn AL, Pearson ER, Antcliff JF et al (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838\u20131849","journal-title":"N Engl J Med"},{"key":"5181_CR14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJMoa061759","volume":"355","author":"ER Pearson","year":"2006","unstructured":"Pearson ER, Flechtner I, Njolstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467\u2013477","journal-title":"N Engl J Med"},{"key":"5181_CR15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJMoa055068","volume":"355","author":"AP Babenko","year":"2006","unstructured":"Babenko AP, Polak M, Cave H et al (2006) Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 355:456\u2013466","journal-title":"N Engl J Med"},{"key":"5181_CR16","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diabetes.53.10.2713","volume":"53","author":"JV Sagen","year":"2004","unstructured":"Sagen JV, Raeder H, Hathout E et al (2004) Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 53:2713\u20132718","journal-title":"Diabetes"},{"key":"5181_CR17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S2213-8587(18)30106-2","volume":"6","author":"P Bowman","year":"2018","unstructured":"Bowman P, Sulen A, Barbetti F et al (2018) Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. Lancet Diabetes Endocrinol 6:637\u2013646","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5181_CR18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jama.2013.283980","volume":"311","author":"AM Steele","year":"2014","unstructured":"Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT (2014) Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 311:279\u2013286","journal-title":"JAMA"},{"key":"5181_CR19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00125-013-3075-x","volume":"57","author":"A Stride","year":"2014","unstructured":"Stride A, Shields B, Gill-Carey O, Chakera AJ, Colclough K, Ellard S et al (2014) Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia 57:54\u201356","journal-title":"Diabetologia"},{"key":"5181_CR20","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","volume":"362","author":"ER Pearson","year":"2003","unstructured":"Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT (2003) Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362:1275\u20131281","journal-title":"Lancet"},{"key":"5181_CR21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-005-1738-y","volume":"48","author":"ER Pearson","year":"2005","unstructured":"Pearson ER, Pruhova S, Tack CJ et al (2005) Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4\u03b1 mutations in a large European collection. Diabetologia 48:878\u2013885","journal-title":"Diabetologia"},{"key":"5181_CR22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00125-011-2319-x","volume":"55","author":"P Bowman","year":"2012","unstructured":"Bowman P, Flanagan SE, Edghill EL et al (2012) Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia 55:123\u2013127","journal-title":"Diabetologia"},{"key":"5181_CR23","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00125-011-2418-8","volume":"55","author":"BM Shields","year":"2012","unstructured":"Shields BM, McDonald TJ, Ellard S, Campbell MJ, Hyde C, Hattersley AT (2012) The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia 55:1265\u20131272","journal-title":"Diabetologia"},{"key":"5181_CR24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2337\/dc19-0747","volume":"43","author":"A Carlsson","year":"2020","unstructured":"Carlsson A, Shepherd M, Ellard S et al (2020) Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should lead to testing for MODY: lessons from a 5-year pediatric Swedish national cohort study. Diabetes Care 43:82\u201389","journal-title":"Diabetes Care"},{"key":"5181_CR25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/JCI133516","volume":"130","author":"S Ellard","year":"2020","unstructured":"Ellard S, Colclough K, Patel KA, Hattersley AT (2020) Prediction algorithms: pitfalls in interpreting genetic variants of autosomal dominant monogenic diabetes. J Clin Invest 130:14\u201316","journal-title":"J Clin Invest"},{"key":"5181_CR26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrneph.2014.232","volume":"11","author":"RL Clissold","year":"2015","unstructured":"Clissold RL, Hamilton AJ, Hattersley AT, Ellard S, Bingham C (2015) HNF1B-associated renal and extra-renal disease-an expanding clinical spectrum. Nat Rev Nephrol 2015 11:102\u2013112","journal-title":"Nat Rev Nephrol 2015"},{"key":"5181_CR27","unstructured":"Tranebjaerg L, Barrett T, Rendtorff ND WFS1 Wolfram syndrome spectrum disorder. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews\u00ae. University of Washington, Seattle. Available from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20301750. Accessed 13 May 2020"},{"key":"5181_CR28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1464-5491.2008.02359.x","volume":"25","author":"R Murphy","year":"2008","unstructured":"Murphy R, Turnbull DM, Walker M, Hattersley AT (2008) Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabet Med 25:383\u2013399","journal-title":"Diabet Med"},{"key":"5181_CR29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2337\/diab.42.2.359","volume":"42","author":"T Tuomi","year":"1993","unstructured":"Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR (1993) Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359\u2013362","journal-title":"Diabetes"},{"key":"5181_CR30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2337\/dc07-1308","volume":"31","author":"S Brophy","year":"2008","unstructured":"Brophy S, Yderstraede K, Mauricio D et al (2008) Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 31:439\u2013441","journal-title":"Diabetes Care"},{"key":"5181_CR31","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2337\/dc12-0931","volume":"36","author":"MI Hawa","year":"2013","unstructured":"Hawa MI, Kolb H, Schloot N et al (2013) Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care 36:908\u2013913","journal-title":"Diabetes Care"},{"key":"5181_CR32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/dc19-0880","volume":"43","author":"M Battaglia","year":"2020","unstructured":"Battaglia M, Ahmed S, Anderson MS et al (2020) Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes. Diabetes Care 43:5\u201312","journal-title":"Diabetes Care"},{"key":"5181_CR33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2337\/dc18-1727","volume":"42","author":"S Onengut-Gumuscu","year":"2019","unstructured":"Onengut-Gumuscu S, Chen WM, Robertson CC et al (2019) Type 1 diabetes risk in African-ancestry participants and utility of an ancestry-specific genetic risk score. Diabetes Care 42:406\u2013415","journal-title":"Diabetes Care"},{"key":"5181_CR34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MED.0000000000000347","volume":"24","author":"SS Rich","year":"2017","unstructured":"Rich SS (2017) Genetics and its potential to improve type 1 diabetes care. Curr Opin Endocrinol Diabetes Obes 24:279\u2013284","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"5181_CR35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/ng.3245","volume":"47","author":"S Onengut-Gumuscu","year":"2015","unstructured":"Onengut-Gumuscu S, Chen WM, Burren O et al (2015) Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet 47:381\u2013386","journal-title":"Nat Genet"},{"key":"5181_CR36","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1172\/JCI134057","volume":"130","author":"MR Rickels","year":"2020","unstructured":"Rickels MR, Evans-Molina C, Bahnson HT et al (2020) High residual C-peptide likely contributes to glycemic control in type 1 diabetes. J Clin Invest 130:1850\u20131862","journal-title":"J Clin Invest"},{"key":"5181_CR37","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2337\/dc16-0360","volume":"39","author":"W Hao","year":"2016","unstructured":"Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ (2016) Fall in C-peptide during first 4 years from diagnosis of type 1 diabetes: variable relation to age, HbA1c, and insulin dose. Diabetes Care 39:1664\u20131670","journal-title":"Diabetes Care"},{"key":"5181_CR38","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.2337\/dc18-0465","volume":"41","author":"BM Shields","year":"2018","unstructured":"Shields BM, McDonald TJ, Oram R et al (2018) C-peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase. Diabetes Care 41:1486\u20131492","journal-title":"Diabetes Care"},{"key":"5181_CR39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist E, Storm P, Karajamaki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6:361\u2013369","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5181_CR40","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","volume":"7","author":"OP Zaharia","year":"2019","unstructured":"Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7:684\u2013694","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5181_CR41","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1373\/clinchem.2007.101287","volume":"54","author":"RR Little","year":"2008","unstructured":"Little RR, Rohlfing CL, Tennill AL et al (2008) Standardization of C-peptide measurements. Clin Chem 54:1023\u20131026","journal-title":"Clin Chem"},{"key":"5181_CR42","doi-asserted-by":"crossref","first-page":"e1002654","DOI":"10.1371\/journal.pmed.1002654","volume":"15","author":"MS Udler","year":"2018","unstructured":"Udler MS, Kim J, von Grotthuss M et al (2018) Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med 15:e1002654","journal-title":"PLoS Med"},{"key":"5181_CR43","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41588-018-0084-1","volume":"50","author":"A Mahajan","year":"2018","unstructured":"Mahajan A, Wessel J, Willems SM et al (2018) Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet 50:559\u2013571","journal-title":"Nat Genet"},{"key":"5181_CR44","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"RA Insel","year":"2015","unstructured":"Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38:1964\u20131974","journal-title":"Diabetes Care"},{"key":"5181_CR45","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00125-013-2960-7","volume":"56","author":"JP Krischer","year":"2013","unstructured":"Krischer JP (2013) The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia 56:1919\u20131924","journal-title":"Diabetologia"},{"key":"5181_CR46","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2013.6285","volume":"309","author":"AG Ziegler","year":"2013","unstructured":"Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309:2473\u20132479","journal-title":"JAMA"},{"key":"5181_CR47","first-page":"11.1","volume-title":"Diabetes in America","author":"M Rewers","year":"2017","unstructured":"Rewers M, Stene LC, Norris JM (2017) Risk factors for type 1 diabetes. In: Cowie CC, Caagrande SS, Menke A et al (eds) Diabetes in America, 3rd edn. NIH, Bethesda, pp 11.1\u201311.29","edition":"3"},{"key":"5181_CR48","first-page":"37.1","volume-title":"Diabetes in America","author":"JS Skyler","year":"2017","unstructured":"Skyler JS, Krischer JP, Becker D, Rewers M (2017) Prevention of type 1 diabetes. In: Cowie CC, Caagrande SS, Menke A et al (eds) Diabetes in America, 3rd edn. NIH, Bethesda, pp 37.1\u201337.21","edition":"3"},{"key":"5181_CR49","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1001\/jama.2014.5610","volume":"311","author":"M Knip","year":"2014","unstructured":"Knip M, Akerblom HK, Becker D et al (2014) Hydrolyzed infant formula and early beta-cell autoimmunity: a randomized clinical trial. JAMA 311:2279\u20132287","journal-title":"JAMA"},{"key":"5181_CR50","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/archpediatrics.2011.1559","volume":"166","author":"O Vaarala","year":"2012","unstructured":"Vaarala O, Ilonen J, Ruohtula T et al (2012) Removal of bovine insulin from cow\u2019s milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med 166:608\u2013614","journal-title":"Arch Pediatr Adolesc Med"},{"key":"5181_CR51","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2337\/dc10-2456","volume":"34","author":"S Hummel","year":"2011","unstructured":"Hummel S, Pfluger M, Hummel M, Bonifacio E, Ziegler AG (2011) Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 34:1301\u20131305","journal-title":"Diabetes Care"},{"key":"5181_CR52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2017.19826","volume":"319","author":"M Knip","year":"2018","unstructured":"Knip M, Akerblom HK, Al Taji E et al (2018) Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: the TRIGR randomized clinical trial. JAMA 319:38\u201348","journal-title":"JAMA"},{"key":"5181_CR53","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/S0140-6736(08)61309-4","volume":"372","author":"K Nanto-Salonen","year":"2008","unstructured":"Nanto-Salonen K, Kupila A, Simell S et al (2008) Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372:1746\u20131755","journal-title":"Lancet"},{"key":"5181_CR54","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2017.17070","volume":"318","author":"JP Krischer","year":"2017","unstructured":"Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ (2017) Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA 318:1891\u20131902","journal-title":"JAMA"},{"key":"5181_CR55","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/pedi.12611","volume":"19","author":"H Elding Larsson","year":"2018","unstructured":"Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J (2018) Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: a randomized clinical trial. Pediatr Diabetes 19:410\u2013419","journal-title":"Pediatr Diabetes"},{"key":"5181_CR56","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2337\/diabetes.47.6.980","volume":"47","author":"EF Lampeter","year":"1998","unstructured":"Lampeter EF, Klinghammer A, Scherbaum WA et al (1998) The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes 47:980\u2013984","journal-title":"Diabetes"},{"key":"5181_CR57","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0140-6736(04)15786-3","volume":"363","author":"EA Gale","year":"2004","unstructured":"Gale EA, Bingley PJ, Emmett CL, Collier T (2004) European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363:925\u2013931","journal-title":"Lancet"},{"key":"5181_CR58","doi-asserted-by":"crossref","unstructured":"(2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346:1685\u20131691","DOI":"10.1056\/NEJMoa012350"},{"key":"5181_CR59","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2337\/dc11-0523","volume":"34","author":"K Vehik","year":"2011","unstructured":"Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP (2011) Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care 34:1585\u20131590","journal-title":"Diabetes Care"},{"key":"5181_CR60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.diabet.2009.02.005","volume":"35","author":"E Vandemeulebroucke","year":"2009","unstructured":"Vandemeulebroucke E, Gorus FK, Decochez K, Weets I, Keymeulen B, De Block C, Tits J, Pipeleers DG, Mathieu C (2009) Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes Metab 35:319\u2013327","journal-title":"Diabetes Metab"},{"key":"5181_CR61","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold KC, Bundy BN, Long SA et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381:603\u2013613","journal-title":"N Engl J Med"},{"key":"5181_CR62","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/QCO.0b013e3283608300","volume":"26","author":"D Hober","year":"2013","unstructured":"Hober D, Alidjinou EK (2013) Enteroviral pathogenesis of type 1 diabetes: queries and answers. Curr Opin Infect Dis 26:263\u2013269","journal-title":"Curr Opin Infect Dis"},{"key":"5181_CR63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/aje\/kwx191","volume":"187","author":"L Hakola","year":"2018","unstructured":"Hakola L, Takkinen HM, Niinisto S et al (2018) Infant feeding in relation to the risk of advanced islet autoimmunity and type 1 diabetes in children with increased genetic susceptibility: a cohort study. Am J Epidemiol 187:34\u201344","journal-title":"Am J Epidemiol"},{"key":"5181_CR64","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2337\/dc18-2176","volume":"42","author":"G Tapia","year":"2019","unstructured":"Tapia G, Marild K, Dahl SR et al (2019) Maternal and newborn vitamin D-binding protein, vitamin D levels, vitamin D receptor genotype, and childhood type 1 diabetes. Diabetes Care 42:553\u2013559","journal-title":"Diabetes Care"},{"key":"5181_CR65","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00125-013-3106-7","volume":"57","author":"JM Norris","year":"2014","unstructured":"Norris JM, Kroehl M, Fingerlin TE et al (2014) Erythrocyte membrane docosapentaenoic acid levels are associated with islet autoimmunity: the Diabetes Autoimmunity Study in the Young. Diabetologia 57:295\u2013304","journal-title":"Diabetologia"},{"key":"5181_CR66","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinte.161.3.397","volume":"161","author":"DECODE Study Group, the European Diabetes Epidemiology Group","year":"2001","unstructured":"DECODE Study Group, the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397\u2013405","journal-title":"Arch Intern Med"},{"key":"5181_CR67","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.2337\/diacare.26.9.2518","volume":"26","author":"Diabetes Prevention Program Research Group","year":"2003","unstructured":"Diabetes Prevention Program Research Group (2003) Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 26:2518\u20132523","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"5181_CR68","first-page":"S152","volume":"43","author":"ADA","year":"2020","unstructured":"ADA (2020) 12. Older adults. In: standards of medical care in diabetes\u20132020. Diabetes Care 43(Suppl 1):S152\u2013S162","journal-title":"Diabetes Care"},{"key":"5181_CR69","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jamainternmed.2017.6040","volume":"177","author":"JS Haw","year":"2017","unstructured":"Haw JS, Galaviz KI, Straus AN et al (2017) Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 177:1808\u20131817","journal-title":"JAMA Intern Med"},{"key":"5181_CR70","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393\u2013403","journal-title":"N Engl J Med"},{"key":"5181_CR71","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/gerona\/61.10.1075","volume":"61","author":"J Crandall","year":"2006","unstructured":"Crandall J, Schade D, Ma Y et al (2006) The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 61:1075\u20131081","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"5181_CR72","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","volume":"374","author":"WC Knowler","year":"2009","unstructured":"Knowler WC, Fowler SE, Hamman RF et al (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374:1677\u20131686","journal-title":"Lancet"},{"key":"5181_CR73","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.2337\/dc14-0018","volume":"37","author":"LM Delahanty","year":"2014","unstructured":"Delahanty LM, Pan Q, Jablonski KA et al (2014) Effects of weight loss, weight cycling, and weight loss maintenance on diabetes incidence and change in cardiometabolic traits in the Diabetes Prevention Program. Diabetes Care 37:2738\u20132745","journal-title":"Diabetes Care"},{"key":"5181_CR74","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.2337\/db15-0441","volume":"64","author":"GD Papandonatos","year":"2015","unstructured":"Papandonatos GD, Pan Q, Pajewski NM et al (2015) Genetic predisposition to weight loss and regain with lifestyle intervention: analyses from the Diabetes Prevention Program and the Look AHEAD randomized controlled trials. Diabetes 64:4312\u20134321","journal-title":"Diabetes"},{"key":"5181_CR75","doi-asserted-by":"crossref","first-page":"e1001647","DOI":"10.1371\/journal.pmed.1001647","volume":"11","author":"C Langenberg","year":"2014","unstructured":"Langenberg C, Sharp SJ, Franks PW et al (2014) Gene-lifestyle interaction and type 2 diabetes: the EPIC interact case-cohort study. PLoS Med 11:e1001647","journal-title":"PLoS Med"},{"key":"5181_CR76","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2337\/db15-0950","volume":"65","author":"MF Hivert","year":"2016","unstructured":"Hivert MF, Christophi CA, Franks PW et al (2016) Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program Participants. Diabetes 65:520\u2013526","journal-title":"Diabetes"},{"key":"5181_CR77","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2337\/db10-1119","volume":"60","author":"MF Hivert","year":"2011","unstructured":"Hivert MF, Jablonski KA, Perreault L et al (2011) Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes 60:1340\u20131348","journal-title":"Diabetes"},{"key":"5181_CR78","doi-asserted-by":"crossref","first-page":"e1001116","DOI":"10.1371\/journal.pmed.1001116","volume":"8","author":"TO Kilpelainen","year":"2011","unstructured":"Kilpelainen TO, Qi L, Brage S et al (2011) Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med 8:e1001116","journal-title":"PLoS Med"},{"key":"5181_CR79","doi-asserted-by":"crossref","first-page":"e1006812","DOI":"10.1371\/journal.pgen.1006812","volume":"13","author":"D Shungin","year":"2017","unstructured":"Shungin D, Deng WQ, Varga TV et al (2017) Ranking and characterization of established BMI and lipid associated loci as candidates for gene-environment interactions. PLoS Genet 13:e1006812","journal-title":"PLoS Genet"},{"key":"5181_CR80","doi-asserted-by":"crossref","first-page":"e1006528","DOI":"10.1371\/journal.pgen.1006528","volume":"13","author":"M Graff","year":"2017","unstructured":"Graff M, Scott RA, Justice AE et al (2017) Genome-wide physical activity interactions in adiposity \u2013 a meta-analysis of 200,452 adults. PLoS Genet 13:e1006528","journal-title":"PLoS Genet"},{"key":"5181_CR81","first-page":"559","volume":"46","author":"J Tyrrell","year":"2017","unstructured":"Tyrrell J, Wood AR, Ames RM et al (2017) Gene-obesogenic environment interactions in the UK Biobank study. Int J Epidemiol 46:559\u2013575","journal-title":"Int J Epidemiol"},{"key":"5181_CR82","doi-asserted-by":"crossref","first-page":"i4707","DOI":"10.1136\/bmj.i4707","volume":"354","author":"KM Livingstone","year":"2016","unstructured":"Livingstone KM, Celis-Morales C, Papandonatos GD et al (2016) FTO genotype and weight loss: systematic review and meta-analysis of 9563 individual participant data from eight randomised controlled trials. BMJ 354:i4707","journal-title":"BMJ"},{"key":"5181_CR83","doi-asserted-by":"crossref","first-page":"e1002185","DOI":"10.1371\/journal.pmed.1002185","volume":"13","author":"JG Godino","year":"2016","unstructured":"Godino JG, van Sluijs EM, Marteau TM, Sutton S, Sharp SJ, Griffin SJ (2016) Lifestyle advice combined with personalized estimates of genetic or phenotypic risk of type 2 diabetes, and objectively measured physical activity: a randomized controlled trial. PLoS Med 13:e1002185","journal-title":"PLoS Med"},{"key":"5181_CR84","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cell.2015.11.001","volume":"163","author":"D Zeevi","year":"2015","unstructured":"Zeevi D, Korem T, Zmora N et al (2015) Personalized nutrition by prediction of glycemic responses. Cell 163:1079\u20131094","journal-title":"Cell"},{"key":"5181_CR85","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.2337\/db10-0543","volume":"59","author":"KA Jablonski","year":"2010","unstructured":"Jablonski KA, McAteer JB, de Bakker PI et al (2010) Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59:2672\u20132681","journal-title":"Diabetes"},{"key":"5181_CR86","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/M18-1605","volume":"170","author":"JW Apolzan","year":"2019","unstructured":"Apolzan JW, Venditti EM, Edelstein SL et al (2019) Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med 170:682\u2013690","journal-title":"Ann Intern Med"},{"key":"5181_CR87","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","volume":"391","author":"ME Lean","year":"2018","unstructured":"Lean ME, Leslie WS, Barnes AC et al (2018) Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 391:541\u2013551","journal-title":"Lancet"},{"key":"5181_CR88","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2147\/CLEP.S179555","volume":"10","author":"JM Dennis","year":"2018","unstructured":"Dennis JM, Shields BM, Jones AG, Pearson ER, Hattersley AT, Henley WE (2018) Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach. Clin Epidemiol 10:1869\u20131877","journal-title":"Clin Epidemiol"},{"key":"5181_CR89","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2337\/dc17-1827","volume":"41","author":"JM Dennis","year":"2018","unstructured":"Dennis JM, Shields BM, Hill AV et al (2018) Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered short- and long-term glycemic response to DPP-4 inhibitor therapy. Diabetes Care 41:705\u2013712","journal-title":"Diabetes Care"},{"key":"5181_CR90","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2337\/dc07-2248","volume":"31","author":"Y Feng","year":"2008","unstructured":"Feng Y, Mao G, Ren X (2008) Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 31:1939\u20131944","journal-title":"Diabetes Care"},{"key":"5181_CR91","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.diabres.2006.10.021","volume":"77","author":"H Zhang","year":"2007","unstructured":"Zhang H, Liu X, Kuang H, Yi R, Xing H (2007) Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res Clin Pract 77:58\u201361","journal-title":"Diabetes Res Clin Pract"},{"key":"5181_CR92","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejim.2011.10.018","volume":"23","author":"M Javorsky","year":"2012","unstructured":"Javorsky M, Klimcakova L, Schroner Z et al (2012) KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med 23:245\u2013249","journal-title":"Eur J Intern Med"},{"key":"5181_CR93","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.2337\/db07-0440","volume":"56","author":"ER Pearson","year":"2007","unstructured":"Pearson ER, Donnelly LA, Kimber C et al (2007) Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 56:2178\u20132182","journal-title":"Diabetes"},{"key":"5181_CR94","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1463-1326.2010.01324.x","volume":"13","author":"Z Schroner","year":"2011","unstructured":"Schroner Z, Javorsky M, Tkacova R et al (2011) Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab 13:89\u201391","journal-title":"Diabetes Obes Metab"},{"key":"5181_CR95","doi-asserted-by":"crossref","first-page":"374858","DOI":"10.1155\/2013\/374858","volume":"2013","author":"M Javorsky","year":"2013","unstructured":"Javorsky M, Babjakova E, Klimcakova L et al (2013) Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide. Int J Endocrinol 2013:374858","journal-title":"Int J Endocrinol"},{"key":"5181_CR96","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.clpt.2005.04.013","volume":"78","author":"ES Kang","year":"2005","unstructured":"Kang ES, Park SY, Kim HJ et al (2005) Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 78:202\u2013208","journal-title":"Clin Pharmacol Ther"},{"key":"5181_CR97","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.metabol.2009.10.030","volume":"59","author":"MC Hsieh","year":"2010","unstructured":"Hsieh MC, Lin KD, Tien KJ et al (2010) Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism 59:1139\u20131144","journal-title":"Metabolism"},{"key":"5181_CR98","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/aps.2012.144","volume":"34","author":"Q Pei","year":"2013","unstructured":"Pei Q, Huang Q, Yang GP et al (2013) PPAR-gamma2 and PTPRD gene polymorphisms influence type 2 diabetes patients\u2019 response to pioglitazone in China. Acta Pharmacol Sin 34:255\u2013261","journal-title":"Acta Pharmacol Sin"},{"key":"5181_CR99","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/ng.735","volume":"43","author":"K Zhou","year":"2011","unstructured":"Zhou K, Bellenguez C, Spencer CC et al (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 43:117\u2013120","journal-title":"Nat Genet"},{"key":"5181_CR100","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ng.3632","volume":"48","author":"K Zhou","year":"2016","unstructured":"Zhou K, Yee SW, Seiser EL et al (2016) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 48:1055\u20131059","journal-title":"Nat Genet"},{"key":"5181_CR101","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41588-018-0241-6","volume":"50","author":"A Mahajan","year":"2018","unstructured":"Mahajan A, Taliun D, Thurner M et al (2018) Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 50:1505\u20131513","journal-title":"Nat Genet"},{"key":"5181_CR102","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/clpt.2009.176","volume":"87","author":"K Zhou","year":"2010","unstructured":"Zhou K, Donnelly L, Burch L et al (2010) Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 87:52\u201356","journal-title":"Clin Pharmacol Ther"},{"key":"5181_CR103","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/dc15-2464","volume":"39","author":"AY Dawed","year":"2016","unstructured":"Dawed AY, Donnelly L, Tavendale R et al (2016) CYP2C8 and SLCO1B1 variants and therapeutic response to thiazolidinediones in patients with type 2 diabetes. Diabetes Care 39:1902\u20131908","journal-title":"Diabetes Care"},{"key":"5181_CR104","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","volume":"117","author":"Y Shu","year":"2007","unstructured":"Shu Y, Sheardown SA, Brown C et al (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422\u20131431","journal-title":"J Clin Invest"},{"key":"5181_CR105","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cpt.701","volume":"102","author":"E Sundelin","year":"2017","unstructured":"Sundelin E, Gormsen LC, Jensen JB et al (2017) Genetic polymorphisms in organic cation transporter 1 attenuates hepatic metformin exposure in humans. Clin Pharmacol Ther 102:841\u2013848","journal-title":"Clin Pharmacol Ther"},{"key":"5181_CR106","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.2337\/db08-0896","volume":"58","author":"K Zhou","year":"2009","unstructured":"Zhou K, Donnelly LA, Kimber CH et al (2009) Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 58:1434\u20131439","journal-title":"Diabetes"},{"key":"5181_CR107","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/cpt.567","volume":"101","author":"T Dujic","year":"2017","unstructured":"Dujic T, Zhou K, Yee SW et al (2017) Variants in pharmacokinetic transporters and glycemic response to metformin: a Metgen meta-analysis. Clin Pharmacol Ther 101:763\u2013772","journal-title":"Clin Pharmacol Ther"},{"key":"5181_CR108","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","volume":"56","author":"YG Kim","year":"2013","unstructured":"Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM (2013) Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56:696\u2013708","journal-title":"Diabetologia"},{"key":"5181_CR109","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/dom.13242","volume":"20","author":"TME Davis","year":"2018","unstructured":"Davis TME, Mulder H, Lokhnygina Y et al (2018) Effect of race on the glycaemic response to sitagliptin: insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab 20:1427\u20131434","journal-title":"Diabetes Obes Metab"},{"key":"5181_CR110","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1210\/jc.2014-1539","volume":"99","author":"LK Williams","year":"2014","unstructured":"Williams LK, Padhukasahasram B, Ahmedani BK et al (2014) Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab 99:3160\u20133168","journal-title":"J Clin Endocrinol Metab"},{"key":"5181_CR111","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2337\/diacare.25.10.1862","volume":"25","author":"C Kim","year":"2002","unstructured":"Kim C, Newton KM, Knopp RH (2002) Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 25:1862\u20131868","journal-title":"Diabetes Care"},{"key":"5181_CR112","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/17446651.2018.1471354","volume":"13","author":"R Das Gupta","year":"2018","unstructured":"Das Gupta R, Gupta S, Das A, Biswas T, Haider MR, Sarker M (2018) Ethnic predisposition of diabetes mellitus in the patients with previous history of gestational diabetes mellitus: a review. Expert Rev Endocrinol Metab 13:149\u2013158","journal-title":"Expert Rev Endocrinol Metab"},{"key":"5181_CR113","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11892-015-0709-z","volume":"16","author":"WL Lowe Jr","year":"2016","unstructured":"Lowe WL Jr, Scholtens DM, Sandler V, Hayes MG (2016) Genetics of gestational diabetes mellitus and maternal metabolism. Curr Diab Rep 16:15","journal-title":"Curr Diab Rep"},{"key":"5181_CR114","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.2337\/db12-1692","volume":"62","author":"MG Hayes","year":"2013","unstructured":"Hayes MG, Urbanek M, Hivert MF et al (2013) Identification of HKDC1 and BACE2 as genes influencing glycemic traits during pregnancy through genome-wide association studies. Diabetes 62:3282\u20133291","journal-title":"Diabetes"},{"key":"5181_CR115","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2337\/dc15-2672","volume":"39","author":"CE Powe","year":"2016","unstructured":"Powe CE, Allard C, Battista MC et al (2016) Heterogeneous contribution of insulin sensitivity and secretion defects to gestational diabetes mellitus. Diabetes Care 39:1052\u20131055","journal-title":"Diabetes Care"},{"key":"5181_CR116","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-019-4961-7","volume":"62","author":"K Benhalima","year":"2019","unstructured":"Benhalima K, Van Crombrugge P, Moyson C et al (2019) Characteristics and pregnancy outcomes across gestational diabetes mellitus subtypes based on insulin resistance. Diabetologia 62:2118\u20132128","journal-title":"Diabetologia"},{"key":"5181_CR117","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13643-019-1151-0","volume":"8","author":"SD Cooray","year":"2019","unstructured":"Cooray SD, Boyle JA, Soldatos G, Wijeyaratne LA, Teede HJ (2019) Prognostic prediction models for pregnancy complications in women with gestational diabetes: a protocol for systematic review, critical appraisal and meta-analysis. Syst Rev 8:270","journal-title":"Syst Rev"},{"key":"5181_CR118","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11892-018-1063-8","volume":"18","author":"DK Tobias","year":"2018","unstructured":"Tobias DK (2018) Prediction and prevention of type 2 diabetes in women with a history of GDM. Curr Diab Rep 18:78","journal-title":"Curr Diab Rep"},{"key":"5181_CR119","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1210\/jc.2014-3761","volume":"100","author":"VR Aroda","year":"2015","unstructured":"Aroda VR, Christophi CA, Edelstein SL et al (2015) The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J Clin Endocrinol Metab 100:1646\u20131653","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"5181_CR120","first-page":"S183","volume":"43","author":"ADA","year":"2020","unstructured":"ADA (2020) 14. Management of diabetes in pregnancy. In: standards of medical care in diabetes\u20132020. Diabetes Care 43(Suppl 1):S183\u2013S192","journal-title":"Diabetes Care"},{"key":"5181_CR121","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1464-5491.2008.02622.x","volume":"26","author":"G Spyer","year":"2009","unstructured":"Spyer G, Macleod KM, Shepherd M, Ellard S, Hattersley AT (2009) Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation. Diabet Med 26:14\u201318","journal-title":"Diabet Med"},{"key":"5181_CR122","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diabres.2019.04.017","volume":"151","author":"M Sanyoura","year":"2019","unstructured":"Sanyoura M, Letourneau L, Knight Johnson AE et al (2019) GCK-MODY in the US Monogenic Diabetes Registry: description of 27 unpublished variants. Diabetes Res Clin Pract 151:231\u2013236","journal-title":"Diabetes Res Clin Pract"},{"key":"5181_CR123","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/dme.13180","volume":"34","author":"E De Franco","year":"2017","unstructured":"De Franco E, Caswell R, Houghton JA, Iotova V, Hattersley AT, Ellard S (2017) Analysis of cell-free fetal DNA for non-invasive prenatal diagnosis in a family with neonatal diabetes. Diabet Med 34:582\u2013585","journal-title":"Diabet Med"},{"key":"5181_CR124","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-8587(15)00045-5","volume":"3","author":"F Petrak","year":"2015","unstructured":"Petrak F, Baumeister H, Skinner TC, Brown A, Holt RIG (2015) Depression and diabetes: treatment and health-care delivery. Lancet Diabetes Endocrinol 3:472\u2013485","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5181_CR125","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S2213-8587(15)00135-7","volume":"3","author":"FJ Snoek","year":"2015","unstructured":"Snoek FJ, Bremmer MA, Hermanns N (2015) Constructs of depression and distress in diabetes: time for an appraisal. Lancet Diabetes Endocrinol 3:450\u2013460","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5181_CR126","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-8587(15)00134-5","volume":"3","author":"CD Moulton","year":"2015","unstructured":"Moulton CD, Pickup JC, Ismail K (2015) The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol 3:461\u2013471","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"5181_CR127","first-page":"S48","volume":"43","author":"ADA","year":"2020","unstructured":"ADA (2020) 5. Facilitating behavior change and well-being to improve health outcomes. In: Standards of medical care in diabetes\u20132020. Diabetes Care 43(Suppl 1):S48\u2013S65","journal-title":"Diabetes Care"},{"key":"5181_CR128","doi-asserted-by":"crossref","unstructured":"Fisher L, Polonsky WH, Hessler D (2019) Addressing diabetes distress in clinical care: a practical guide. Diabet Med 36:803\u2013812","DOI":"10.1111\/dme.13967"},{"key":"5181_CR129","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s00125-010-1799-4","volume":"53","author":"BM Shields","year":"2010","unstructured":"Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S (2010) Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53:2504\u20132508","journal-title":"Diabetologia"},{"key":"5181_CR130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.7861\/clinmedicine.14-2-117","volume":"14","author":"M Shepherd","year":"2014","unstructured":"Shepherd M, Colclough K, Ellard S, Hattersley AT (2014) Ten years of the national genetic diabetes nurse network: a model for the translation of genetic information into clinical care. Clin Med (Lond) 14:117\u2013121","journal-title":"Clin Med (Lond)"},{"key":"5181_CR131","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.gde.2018.04.006","volume":"50","author":"KR Owen","year":"2018","unstructured":"Owen KR (2018) Monogenic diabetes in adults: what are the new developments? Curr Opin Genet Dev 50:103\u2013110","journal-title":"Curr Opin Genet Dev"},{"key":"5181_CR132","doi-asserted-by":"crossref","first-page":"2742565","DOI":"10.1155\/2018\/2742565","volume":"2018","author":"A Poudel","year":"2018","unstructured":"Poudel A, Zhou JY, Story D, Li L (2018) Diabetes and associated cardiovascular complications in American Indians\/Alaskan Natives: a review of risks and prevention strategies. J Diabetes Res 2018:2742565","journal-title":"J Diabetes Res"},{"key":"5181_CR133","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11892-019-1125-6","volume":"19","author":"N Al Busaidi","year":"2019","unstructured":"Al Busaidi N, Shanmugam P, Manoharan D (2019) Diabetes in the Middle East: government health care policies and strategies that address the growing diabetes prevalence in the Middle East. Curr Diab Rep 19:8","journal-title":"Curr Diab Rep"},{"key":"5181_CR134","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.2337\/dc16-1762","volume":"39","author":"RJ Meyer","year":"2016","unstructured":"Meyer RJ (2016) Precision medicine, diabetes, and the U.S. Food and Drug Administration. Diabetes Care 39:1874\u20131878","journal-title":"Diabetes Care"},{"key":"5181_CR135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11892-019-1140-7","volume":"19","author":"R Naylor","year":"2019","unstructured":"Naylor R (2019) Economics of genetic testing for diabetes. Curr Diab Rep 19:23","journal-title":"Curr Diab Rep"},{"key":"5181_CR136","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2337\/dbi17-0045","volume":"67","author":"H Fitipaldi","year":"2018","unstructured":"Fitipaldi H, McCarthy MI, Florez JC, Franks PW (2018) A global overview of precision medicine in type 2 diabetes. Diabetes 67:1911\u20131922","journal-title":"Diabetes"},{"key":"5181_CR137","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/326405a0","volume":"326","author":"RL O\u2019Brien","year":"1987","unstructured":"O\u2019Brien RL, Brinster RL, Storb U (1987) Somatic hypermutation of an immunoglobulin transgene in kappa transgenic mice. Nature 326:405\u2013409","journal-title":"Nature"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05181-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-020-05181-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05181-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T00:03:58Z","timestamp":1624061038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-020-05181-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":137,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5181"],"URL":"https:\/\/doi.org\/10.1007\/s00125-020-05181-w","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,19]]},"assertion":[{"value":"19 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}